Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer.

Autor: Chakravarthi BV; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL., Dedigama-Arachchige P; Vattikuti Urology Institute, Department of Urology, Henry Ford Health System, Detroit, MI., Carskadon S; Vattikuti Urology Institute, Department of Urology, Henry Ford Health System, Detroit, MI., Sundaram SK; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI., Li J; Department of Public Health Sciences, Henry Ford Health System, Detroit, MI., Wu KH; Department of Public Health Sciences, Henry Ford Health System, Detroit, MI., Chandrashekar DS; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL., Peabody JO; Vattikuti Urology Institute, Department of Urology, Henry Ford Health System, Detroit, MI., Stricker H; Vattikuti Urology Institute, Department of Urology, Henry Ford Health System, Detroit, MI., Hwang C; Department of Hematology and Oncology, Henry Ford Health System, Detroit, MI., Chitale DA; Department of Pathology, Henry Ford Health System, Detroit, MI., Williamson SR; Department of Pathology, Henry Ford Health System, Detroit, MI., Gupta NS; Department of Pathology, Henry Ford Health System, Detroit, MI., Navone NM; Department of Genitourinary Medical Oncology-The University of Texas, M D, Anderson Cancer Center, TX., Rogers C; Vattikuti Urology Institute, Department of Urology, Henry Ford Health System, Detroit, MI., Menon M; Vattikuti Urology Institute, Department of Urology, Henry Ford Health System, Detroit, MI., Varambally S; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL., Palanisamy N; Vattikuti Urology Institute, Department of Urology, Henry Ford Health System, Detroit, MI. Electronic address: npalani1@hfhs.org.

Publikováno v: Neoplasia (New York, N.Y.) [Neoplasia] 2019 Oct; Vol. 21 (10), pp. 989-1002. Date of Electronic Publication: 2019 Aug 22.

MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer.

Autor: Chakravarthi BV; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.; Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA., Goswami MT; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.; Department of Pathology, University of Michigan, Ann Arbor, MI, USA., Pathi SS; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.; Department of Pathology, University of Michigan, Ann Arbor, MI, USA., Robinson AD; Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA., Cieślik M; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.; Department of Pathology, University of Michigan, Ann Arbor, MI, USA., Chandrashekar DS; Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA., Agarwal S; Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA., Siddiqui J; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA., Daignault S; Center for Cancer Biostatistics, Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA., Carskadon SL; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.; Department of Pathology, University of Michigan, Ann Arbor, MI, USA., Jing X; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.; Department of Pathology, University of Michigan, Ann Arbor, MI, USA., Chinnaiyan AM; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.; Department of Urology, University of Michigan, Ann Arbor, MI, USA.; Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI, USA.; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA., Kunju LP; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.; Department of Pathology, University of Michigan, Ann Arbor, MI, USA., Palanisamy N; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA., Varambally S; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.; Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA.; Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.

Publikováno v: Oncogene [Oncogene] 2016 Dec 08; Vol. 35 (49), pp. 6330-6340. Date of Electronic Publication: 2016 Jun 06.

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.

Autor: Beltran H; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA.; Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA.; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, New York. USA., Prandi D; Centre for Integrative Biology, University of Trento, Trento, Italy., Mosquera JM; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA.; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA., Benelli M; Centre for Integrative Biology, University of Trento, Trento, Italy., Puca L; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA., Cyrta J; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA., Marotz C; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA., Giannopoulou E; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York, USA., Chakravarthi BV; Department of Pathology, University of Alabama, Birmingham, Alabama, USA., Varambally S; Department of Pathology, University of Alabama, Birmingham, Alabama, USA., Tomlins SA; Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA., Nanus DM; Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA.; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, New York. USA., Tagawa ST; Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA.; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, New York. USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, Cambridge, Massachusetts, USA., Elemento O; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA.; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York, USA., Sboner A; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA.; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York, USA., Garraway LA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, Cambridge, Massachusetts, USA.; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA., Rubin MA; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA.; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, New York. USA.; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA., Demichelis F; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA.; Centre for Integrative Biology, University of Trento, Trento, Italy.; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York, USA.

Publikováno v: Nature medicine [Nat Med] 2016 Mar; Vol. 22 (3), pp. 298-305. Date of Electronic Publication: 2016 Feb 08.

The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.

Autor: Chakravarthi BV; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan., Pathi SS; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan; These authors contributted equally to this work., Goswami MT; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan; These authors contributted equally to this work., Cieślik M; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan., Zheng H; Michigan Center for Translational Pathology, University of Michigan., Nallasivam S; Michigan Center for Translational Pathology, University of Michigan., Arekapudi SR; Michigan Center for Translational Pathology, University of Michigan; Present Address: Department of Hematology and Oncology, Providence Hospital and Medical Center, Southfiled, MI 48075, USA., Jing X; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan., Siddiqui J; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan., Athanikar J; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan., Carskadon SL; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan., Lonigro RJ; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan., Kunju LP; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan., Chinnaiyan AM; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan; Department of Urology, University of Michigan; Howard Hughes Medical Institute, University of Michigan Medical School; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA., Palanisamy N; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA., Varambally S; Michigan Center for Translational Pathology; Department of Pathology, University of Michigan; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Publikováno v: Oncotarget [Oncotarget] 2014 Aug 30; Vol. 5 (16), pp. 6654-69.

Inhibition of cancer cell proliferation and apoptosis-inducing activity of fungal taxol and its precursor baccatin III purified from endophytic Fusarium solani.

Autor: Chakravarthi BV, Sujay R, Kuriakose GC, Karande AA, Jayabaskaran C; Department of Biochemistry, Indian Institute of Science, Bangalore 560012, India. cjb@biochem.iisc.ernet.in.

Publikováno v: Cancer cell international [Cancer Cell Int] 2013 Oct 23; Vol. 13 (1), pp. 105. Date of Electronic Publication: 2013 Oct 23.